These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 32934314)

  • 1. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
    Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
    Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
    Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
    Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis.
    Zhou Y; Zhang J; Li H; Huang T; Wong CC; Wu F; Wu M; Weng N; Liu L; Cheng ASL; Yu J; Wong N; Lo KW; Tang PMK; Kang W; To KF
    Oncogene; 2020 May; 39(22):4375-4389. PubMed ID: 32313226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
    Kwak Y; Cho H; Hur W; Sim T
    Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis.
    Kang W; Huang T; Zhou Y; Zhang J; Lung RWM; Tong JHM; Chan AWH; Zhang B; Wong CC; Wu F; Dong Y; Wang S; Yang W; Pan Y; Chak WP; Cheung AHK; Pang JCS; Yu J; Cheng ASL; To KF
    Cell Death Dis; 2018 Jan; 9(2):92. PubMed ID: 29367737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The transcription factor RUNX2 fuels YAP1 signaling and gastric cancer tumorigenesis.
    Guo Z; Zhou K; Wang Q; Huang Y; Ji J; Peng Y; Zhang X; Zheng T; Zhang Z; Chong D; Yang Z
    Cancer Sci; 2021 Sep; 112(9):3533-3544. PubMed ID: 34160112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
    Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
    Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway.
    Huang T; Liu D; Wang Y; Li P; Sun L; Xiong H; Dai Y; Zou M; Yuan X; Qiu H
    Cell Physiol Biochem; 2018; 50(4):1332-1345. PubMed ID: 30355943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA LINC00649 regulates YES-associated protein 1 (YAP1)/Hippo pathway to accelerate gastric cancer (GC) progression via sequestering miR-16-5p.
    Wang H; Di X; Bi Y; Sun S; Wang T
    Bioengineered; 2021 Dec; 12(1):1791-1802. PubMed ID: 33975517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
    Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
    Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis.
    Kang W; Tong JH; Chan AW; Lee TL; Lung RW; Leung PP; So KK; Wu K; Fan D; Yu J; Sung JJ; To KF
    Clin Cancer Res; 2011 Apr; 17(8):2130-9. PubMed ID: 21346147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo.
    Sun D; Li X; He Y; Li W; Wang Y; Wang H; Jiang S; Xin Y
    Oncotarget; 2016 Dec; 7(49):81062-81076. PubMed ID: 27835600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circular RNA YAP1 inhibits the proliferation and invasion of gastric cancer cells by regulating the miR-367-5p/p27
    Liu H; Liu Y; Bian Z; Zhang J; Zhang R; Chen X; Huang Y; Wang Y; Zhu J
    Mol Cancer; 2018 Oct; 17(1):151. PubMed ID: 30336780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
    Pearson A; Smyth E; Babina IS; Herrera-Abreu MT; Tarazona N; Peckitt C; Kilgour E; Smith NR; Geh C; Rooney C; Cutts R; Campbell J; Ning J; Fenwick K; Swain A; Brown G; Chua S; Thomas A; Johnston SRD; Ajaz M; Sumpter K; Gillbanks A; Watkins D; Chau I; Popat S; Cunningham D; Turner NC
    Cancer Discov; 2016 Aug; 6(8):838-851. PubMed ID: 27179038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
    Van Cutsem E; Bang YJ; Mansoor W; Petty RD; Chao Y; Cunningham D; Ferry DR; Smith NR; Frewer P; Ratnayake J; Stockman PK; Kilgour E; Landers D
    Ann Oncol; 2017 Jun; 28(6):1316-1324. PubMed ID: 29177434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p.
    Zhang J; Zhou Y; Huang T; Wu F; Pan Y; Dong Y; Wang Y; Chan AKY; Liu L; Kwan JSH; Cheung AHK; Wong CC; Lo AKF; Cheng ASL; Yu J; Lo KW; Kang W; To KF
    Oncogene; 2019 Jan; 38(1):33-46. PubMed ID: 30082912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel YAP1/SLC35B4 regulatory axis contributes to proliferation and progression of gastric carcinoma.
    Liu J; Zhao X; Wang K; Zhang X; Yu Y; Lv Y; Zhang S; Zhang L; Guo Y; Li Y; Yang A; Zhang R; Li J
    Cell Death Dis; 2019 Jun; 10(6):452. PubMed ID: 31175271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β.
    Lau WM; Teng E; Huang KK; Tan JW; Das K; Zang Z; Chia T; Teh M; Kono K; Yong WP; Shabbir A; Tay A; Phua NS; Tan P; Chan SL; So JBY
    Mol Cancer Ther; 2018 Jan; 17(1):232-242. PubMed ID: 28978722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.